Want to see HK:1763 full AI Analyst Report?
1763 Stock Chart & Stats
HK$23.52
-HK$0.08(-0.76%)
At close: 4:00 PM EST
HK$23.52
-HK$0.08(-0.76%)
Day’s Range― - ―
52-Week RangeHK$14.32 - HK$25.00
Previous CloseN/A
Volume52.80K
Average Volume (3M)508.32K
Market Cap
HK$5.45B
Enterprise ValueHK$5.46B
Total Cash (Recent Filing)HK$2.59B
Total Debt (Recent Filing)HK$2.73B
Price to Earnings (P/E)14.3
Beta0.76
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.76%
Share Statistics
EPS (TTM)1.00
Shares Outstanding79,968,800
10 Day Avg. Volume533,840
30 Day Avg. Volume508,324
Financial Highlights & Ratios
PEG Ratio-0.85
Price to Book (P/B)1.11
Price to Sales (P/S)0.83
P/FCF Ratio-119.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.76
Revenue Forecast (FY)HK$9.04B
Bulls Say, Bears Say
Bulls Say
High Operating ProfitabilitySustained mid-teens EBITDA and double-digit EBIT margins indicate a structurally profitable core business in isotope and irradiation services. Durable operating margins provide a buffer against demand swings, support reinvestment in specialty technology, and underpin long-term cash generation even if top-line growth slows.
Adequate Capitalization And Asset BaseA moderate leverage profile and a growing equity base support the company’s asset-heavy operations and regulatory capital needs in radiation businesses. Adequate capitalization preserves funding flexibility for maintenance capex, safety compliance and selective expansion over the medium term, reducing solvency risk.
Improved Operating Cash Flow In 2025A sharp improvement in operating cash flow signals better core cash conversion from operations, strengthening liquidity for working capital and reinvestment. If sustained, higher OCF enhances self-funding capacity for capex and reduces reliance on external financing over the medium term.
Bears Say
Revenue Contraction In 2025A material revenue decline after prior growth suggests demand weakness or competitive/market pressures that could persist. Lower top-line reduces operating leverage benefits, limits ability to scale fixed-cost recovery, and constrains future reinvestment and margin stability if not reversed.
Thin Net Margin And CompressionLow net margin limits retained earnings and resilience to shocks despite healthy gross and operating margins. Weak bottom-line conversion constrains dividend sustainability, slows equity accumulation, and reduces the cushion available for strategic investments or regulatory cost increases.
Highly Volatile Free Cash FlowLarge swings and prior significant negative FCF indicate inconsistent cash conversion and timing risk from capex or working capital. Volatile FCF undermines predictable funding for growth, increases refinancing and liquidity risk, and complicates capital allocation over the next several quarters.
China Isotope & Radiation Corp. News
1763 FAQ
What was China Isotope & Radiation Corp.’s price range in the past 12 months?
China Isotope & Radiation Corp. lowest stock price was HK$14.32 and its highest was HK$25.00 in the past 12 months.
What is China Isotope & Radiation Corp.’s market cap?
China Isotope & Radiation Corp.’s market cap is HK$5.45B.
When is China Isotope & Radiation Corp.’s upcoming earnings report date?
China Isotope & Radiation Corp.’s upcoming earnings report date is Aug 27, 2026 which is in 44 days.
How were China Isotope & Radiation Corp.’s earnings last quarter?
China Isotope & Radiation Corp. released its earnings results on Mar 27, 2026. The company reported HK$0.532 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.532.
Is China Isotope & Radiation Corp. overvalued?
According to Wall Street analysts China Isotope & Radiation Corp.’s price is currently Overvalued.
Does China Isotope & Radiation Corp. pay dividends?
China Isotope & Radiation Corp. pays a Monthly dividend of HK$0.26 which represents an annual dividend yield of 2.76%. See more information on China Isotope & Radiation Corp. dividends here
What is China Isotope & Radiation Corp.’s EPS estimate?
China Isotope & Radiation Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Isotope & Radiation Corp. have?
China Isotope & Radiation Corp. has 79,968,800 shares outstanding.
What happened to China Isotope & Radiation Corp.’s price movement after its last earnings report?
China Isotope & Radiation Corp. reported an EPS of HK$0.532 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.528%.
Which hedge fund is a major shareholder of China Isotope & Radiation Corp.?
Currently, no hedge funds are holding shares in HK:1763
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Isotope & Radiation Corp. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
111.84%
12-Months-Change
Fundamentals
Return on Equity
6.19%
Trailing 12-Months
Asset Growth
11.39%
Trailing 12-Months
Company Description
China Isotope & Radiation Corp.
China Isotope & Radiation Corporation is dedicated to the development, production, and distribution of diagnostic and therapeutic radiopharmaceuticals, as well as radioactive source products for both medical and industrial applications throughout China. The company's operations are divided into five principal areas. Its Pharmaceuticals division focuses on creating and marketing imaging diagnostic and therapeutic radiopharmaceuticals, UBT kits and analyzers, and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment furnishes medical and industrial radioactive sources, along with associated technical support services. The Irradiation segment offers sterilization services for products such as medical devices, food, traditional Chinese medicine, and cosmetics, in addition to providing engineering, procurement, and construction (EPC) services for gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment handles the sale of radiation therapy equipment and its corresponding maintenance. Finally, the Independent Clinical Medical and Laboratory Services, and Other Business segment delivers independent clinical laboratory services to hospitals and other medical institutions, covering a range of conditions including hepatitis, endocrine disorders, bone metabolism issues, cardiovascular diseases, and diabetes. Founded in 1983, the company's main office is located in Beijing, China, and it operates as a subsidiary of China National Nuclear Corporation.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―
Options Prices
Currently, No data available
---